Tolerogenic dendritic cells: promising cell therapy for acute kidney injury

Yasuna Nakamura; Tsuyoshi Inoue

doi:10.1016/j.kint.2023.06.015

Tolerogenic dendritic cells: promising cell therapy for acute kidney injury

Kidney Int. 2023 Sep;104(3):420-422. doi: 10.1016/j.kint.2023.06.015.

Authors

Yasuna Nakamura¹, Tsuyoshi Inoue²

Affiliations

¹ Department of Physiology of Visceral Function and Body Fluid, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
² Department of Physiology of Visceral Function and Body Fluid, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. Electronic address: ts-inoue@nagasaki-u.ac.jp.

PMID: 37599014
DOI: 10.1016/j.kint.2023.06.015

Abstract

There is still no established treatment for acute kidney injury (AKI), and the intervention of AKI remains limited to supportive treatments. Li et al. demonstrated the mechanism by which immune tolerance by dendritic cell ameliorates AKI in a mouse ischemia-reperfusion injury model. The phase I/II clinical trials of tolerogenic dendritic cell therapy have been conducted for kidney transplantation, so it is expected to have potential as a cell therapy for AKI in the future.

Publication types

Editorial
Comment

MeSH terms

Acute Kidney Injury* / therapy
Animals
Cell- and Tissue-Based Therapy
Dendritic Cells
Disease Models, Animal
Kidney Transplantation*
Mice